Le Lézard
Classified in: Health, Business
Subjects: PDT, CXP, FVT

Crunch Franchise Announces Newest Location in Urbandale, Iowa


URBANDALE, Iowa, Oct. 19, 2023 /PRNewswire/ -- Crunch Franchise today announced the upcoming December 2023 opening of Crunch Urbandale, a 43,000-square-foot fitness facility, with $5 million dollars' worth of state-of-the-art equipment. Crunch Urbandale is located in a newly renovated space at 8501 Hickman Rd., previously occupied by AMC Movie Theater.

Fusing fitness with entertainment to make serious exercise fun, Crunch Urbandale will offer top-quality strength training amenities, including one of the largest selections of free weights, multiple Olympic platforms and a full line of Hammer Strength training equipment. Additionally, Crunch Urbandale members will have access to cardio equipment, circuit and personal training, a functional training area with indoor turf, dedicated group fitness and ride studios, tanning beds, HydroMassage® beds, and more. Members looking for assistance reaching their goals will have access to our staff of highly experienced personal trainers.

Crunch Urbandale is owned by Fitness Ventures, LLC, one of the fastest growing franchisees in the Crunch system with numerous locations throughout the U.S. Crunch Urbandale will be the 43rd location nationwide for Fitness Ventures, LLC, and their first location in Iowa. "We are excited to bring the Crunch brand to Urbandale," said CEO Brian Hibbard. "Crunch is for everyone, from the first-time gym-goer to the seasoned athlete."

Crunch is known for its innovative group fitness programming and will offer a wide range of classes every week, including 70 proprietary classes that can only be found at Crunch. Class examples include BodyWeb with TRX®, Zumba®, Cardio Tai Box, Yoga Body Sculpt and Fat Burning Pilates. Members looking for additional guidance or motivation can utilize the HIITZonetm, a proprietary high-intensity interval group training program.

Prospective members can now visit https://www.crunchurbandale.com or call 515.259.6688 to reserve memberships at discounted rates beginning at $9.99 per month. Founding members can receive a pre-sale rate with $1 enrollment and one month free, in addition to free t-shirts, discounts on small group and personal training, and more.

Crunch is a gym that believes in making serious exercise fun by fusing fitness and entertainment and pioneering a philosophy of 'No Judgments.' Crunch serves a fitness community for all kinds of people with all types of goals, exercising all different ways, working it out at the same place together. Today, we are renowned for creating one-of-a-kind group fitness classes and unique programming for our wildly diverse members. Headquartered in New York City, Crunch serves two million members with over 440 gyms worldwide in 37 states, the District of Columbia, Australia, Canada, Costa Rica, Portugal, Puerto Rico, and Spain. Crunch is rapidly expanding across the U.S. and around the globe.

SOURCE Crunch


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: